 Judy interpreted this outcome as an indication that patients with baseline low cardiac function are at risk for cardio-toxicity caused by adriamycin therapy.Judy and the SIBR Research group have supplemented several Parkinson's patients with Coenzyme Q10 in the period from 1995 to 2019.Coenzyme Q10 supplementation has been found to decrease the progression of Parkinson's disease in early-onset Parkinson's disease but not in patients with full-blown disabling disease.